netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Everolimus found 11 matches
Open monograph to display formulary status BNF Category
  Everolimus  (Afinitor®, Votubia®) Malignant disease and immunosuppression - Protein kinase inhibitors - 08.01.05
  Lenvatinib  (Kisplyx®) Malignant disease and immunosuppression - Protein kinase inhibitors - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Clinical Commissioning Policy Statement: Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis (08.01.05)
link in drug section Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (08.01.05)
link in drug section NICE TA348: Everolimus for preventing organ rejection in liver transplantation (08.01.05)
link in drug section NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (08.01.05)
link in drug section NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment (08.01.05)
link in drug section NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (08.01.05)
link in drug section NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (08.01.05)
link in drug section NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (08.01.05)
link in drug section NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (08.01.05)


 
netFormulary